Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and
safety of PM01183 in previously treated patients with advanced solid tumors